Together with a consortium of European researchers, neurologist and Radboudumc PI Bart van de Warrenburg and RIHS researcher Marjan Meinders have received a 2 million euro grant for research into rare neurological movement disorders: spastic ataxia. The grant is part of the European Joint Programme on Rare Diseases (EJP-RD). The Radboudumc is a recognized expert centre for rare and genetic movement disorders, including ataxia.
The PROSPAX consortium will develop new tools to track progression of these diseases, such as blood-based biomarkers, specific MRI measurements and wearable technology. The Radboudumc and Donders team will lead the work on wearables, and they will design algorithms that, based on data collected through smartphones and smartwatches, reliably track progression of disease. The ultimate aim is to develop an app that integrates the sensoring data and algorithms, and that can be used as a tool to monitor disease progression in future clinical trials.
The Expert centre for Parkinson & Movement disorders of the Radboudumc has a lot of experience with wearable technology research, and the team will now exploit this knowledge for ataxia.
Related news items
1.5 million euro grant for research into earlier recognition of Parkinson's disease27 October 2021
Researchers aim to improve identification of early symptoms and subtypes of Parkinson's disease with large international studyread more
BRAINMODEL: precision medicine for brain disorders25 October 2021
A team of researchers from Radboudumc, VU Amsterdam and other institutes is going to look for new and better ways to heal developmental disorders in the brain.read more
How healthy is James Bond? - A flu to a kill No time to die: the pathogens surrounding secret agent 00721 October 2021
James Bond made a total of 25 films between 1962 and 2021. In all those films, secret agent 007 washed his hands only twice, even though he often stayed in not so hygienic places with considerable health risks. Radboudumc researchers examined all the health risks in the 47 countries Bond visited.read more
Surprisingly dominant cause underlying type I congenital defect of glycosylation21 October 2021
Alex Garanto, Melissa Bärenfänger, Mirian Janssen, and Dirk Lefeber published a new study, identifying a surprisingly dominant genetic cause underlying type I congenital defect of glycosylation with neuromusculoskeletal phenotypes.read more
Sensitive blood-test as a patient-friendly alternative for bone marrow-based cancer monitoring20 October 2021
Hans Jacobs and Pieter Langerhorst, theme Cancer development and immune defense, and colleagues are one step closer to implementation of personalized diagnostics for bone marrow-based cancer monitoring.read more